ArticleJournal of managed care & specialty pharmacy2022

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.

Ching-Yu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.